Kalaris Therapeutics
KLRS | NASDAQ
$1.46
-$0.11 (-7.30%)
At close: Nov 16, 2026, 4:00 PM ET
$1.46
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Kalaris Therapeutics Company Profile
Company profile explainedCompany Profile
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Key Executives
| Name | Position |
|---|---|
| Andrew Oxtoby | President, Chief Executive Officer & Director |
| Liisa Ann Bayko | Chief Financial Officer & Treasurer |
| Amy Vandekop | Interim Principal Accounting Officer & Corporate Controller |
| Jill E. Porter | Senior Vice President of CMC |
| Kristine Curtiss | Senior Vice President of Clinical |
| Matthew Feinsod | Chief Medical Officer |
| Michael Philip Dybbs | Director & Co-Founder |
| Napoleone Ferrara | Independent Director & Co-Founder |
| Srinivas Akkaraju | Director & Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Kalaris Therapeutics
| Country | United States |
| IPO Date | Jul 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Andrew Oxtoby |
Contact Details
400 Connell Drive Berkeley Heights,
New Jersey 07922 United States
Stock Details
| Ticker Symbol | KLRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001754068 |
| CUSIP Number | 482929106 |
| ISIN Number | US4829291065 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove KLRS